Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Endocrine 2Thoracic 1NET 1CNS 1Breast 1

Conditions

Thymoma 1

Interventions

Carboplatin 41Cisplatin 40Paclitaxel 35Radiotherapy 32Docetaxel 19Pemetrexed 18Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 10Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Octreotide × Thoracic × Clear all
NCT00003283 2023-06-15

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Eastern Cooperative Oncology Group

Phase 2 Completed
38 enrolled
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡